Please login or register to print this page.

ARTICLE CONTRIBUTORS

Boehringer Ingelheim

News & Views

DABIGATRAN DEATHS PROMPT JAPANESE SAFETY ADVISORY

Dabigatran has the potential for serious adverse events, according to a safety warning issued recently by the Japanese Ministry of Health, Labour and Welfare after the deaths of five patients.

The advisory cites 81 cases of serious side effects since the drug’s Japanese launch in January.  Boehringer Ingelheim has advised physicians to carefully monitor for signs of renal impairment or abnormal bleeding, recommending renal-function tests before and during treatment.

The company is now working to ensure that labeling gives patients all relevant information on the drug’s benefits and risks.  Warning is particularly focused on elderly patients and those with risk factors for bleeding.

Published on: September 7, 2011

Members Area

Log in or Register now.

SEARCH THE SITE

RSS FEED

Subscribe to our RSS feed
home

GET EXCLUSIVE UPDATES

Sign up for our regular email newsletters & be the first to know about fresh articles and site updates.

RECENT COMMENTS

    None Found

ENDORSED BY

  • ArrhythmiaAlliance
  • Stars
  • Anticoagulation Europe
  • Atrial Fibrillation Association
 

You are not logged in

You need to be a member to print this page.
Sign up for free membership, or log in.

You are not logged in

You need to be a member to download PDF's.
Sign up for free membership, or log in.